Kristen Killen, MD
Family Medicine · Nixa, MONPI 1144679960
Payments from drug & device makers
Across 260 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$756
- Boehringer Ingelheim$482
- Lilly USA, LLC$405
- AstraZeneca$393
- Novo Nordisk$336
- Johnson & Johnson$300
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,753100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 54 | $756 |
| Boehringer Ingelheim | 35 | $482 |
| Lilly USA, LLC | 32 | $405 |
| AstraZeneca | 25 | $393 |
| Novo Nordisk | 21 | $336 |
| Johnson & Johnson | 25 | $300 |
| AbbVie(2 entities) | 13 | $167 |
| GSK | 10 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $137 |
| Grifols USA, LLC | 1 | $98 |
| Amgen | 5 | $91 |
| Abbott | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 3 | $44 |
| Radius Health, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Antares Pharma, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$3,754 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $189,462 |
| TrulicityDulaglutide | 42 | $68,537 |
| OzempicSemaglutide | 58 | $67,980 |
| JardianceEmpagliflozin | 50 | $63,463 |
| XareltoRivaroxaban | 48 | $50,125 |
| CreonLipase/Protease/Amylase | 12 | $48,300 |
| LinzessLinaclotide | 56 | $45,778 |
| FarxigaDapagliflozin Propanediol | 52 | $43,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,247 |
| Spiriva RespimatTiotropium Bromide | 19 | $14,771 |
| EntrestoSacubitril/Valsartan | 14 | $14,312 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $14,123 |
| UbrelvyUbrogepant | 11 | $13,229 |
| Repatha SureclickEvolocumab | 13 | $12,855 |
| ZenpepLipase/Protease/Amylase | 12 | $10,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $756 | $196,586241 claims |
| AbbVieCreon, Linzess, Ubrelvy | $167 | $107,30779 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $482 | $85,42780 claims |
| Lilly USA, LLCTrulicity | $405 | $68,53742 claims |
| Novo NordiskOzempic | $336 | $67,98058 claims |
| AstraZenecaFarxiga, Symbicort | $393 | $57,54897 claims |
| Johnson & JohnsonXarelto | $300 | $50,12548 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $146 | $30,96152 claims |
| NovartisEntresto | $12 | $14,31214 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $5,87413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Nixa
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.